Endemic Burkitt’s Lymphoma

  • Elizabeth Molyneux
  • Trijn Israels
  • Thomas Walwyn
Part of the Current Cancer Research book series (CUCR)


Endemic Burkitt’s lymphoma is the most common childhood tumour in parts of the world where malaria is holo-endemic. It is highly chemo-sensitive and cure rates are excellent if treated early and aggressively. Unfortunately many children arrive late and live where neither the treatment nor the supportive care is optimal.

The presentation and complications of endemic Burkitt’s lymphoma and complications and protocols of varying intensity used to treat these children with their outcomes are presented.


Epstein Barr Virus Tumour Lysis Syndrome Palliative Care Team Mulago Hospital Bone Marrow Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46(197):218–223PubMedCrossRefGoogle Scholar
  2. 2.
    O’Conor GT, Davies JN (1960) Malignant tumors in African children. With special reference to malignant lymphoma. J Pediatr 56:526–535PubMedCrossRefGoogle Scholar
  3. 3.
    Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt’s lymhoma. Lancet 1(7335):702–703PubMedCrossRefGoogle Scholar
  4. 4.
    Burkitt D (1962) A “tumour safari” in East and Central Africa. Br J Cancer 16:379–386PubMedCrossRefGoogle Scholar
  5. 5.
    Burkitt D (1962) Determining the climatic limitations of a children’s cancer common in Africa. Br Med J 2(5311):1019–1023PubMedCrossRefGoogle Scholar
  6. 6.
    Cook-Mozaffari P, Newton R, Beral V et al (1998) The geographical distribution of Kaposi’s sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer 78(11):1521–1528PubMedCrossRefGoogle Scholar
  7. 7.
    Rainey JJ, Mwanda WO, Wairiumu P et al (2007) Spatial distribution of Burkitt’s lymphoma in Kenya and association with malaria risk. Trop Med Int Health 12(8):936–943PubMedCrossRefGoogle Scholar
  8. 8.
    de-The G (1977) Is Burkitt’s lymphoma related to perinatal infection by Epstein-Barr virus? Lancet 1(8007):335–338PubMedCrossRefGoogle Scholar
  9. 9.
    Burkitt D (1963) A children’s cancer dependent on environment. 17th Annual Symposium on Fundamental Cancer Research in Viruses, Nucleic Acids and Cancer, pp 615–629Google Scholar
  10. 10.
    Cardy AH, Sharp L, Little J (2001) Burkitt’s lymphoma: a review of the epidemiology. Kuwait Med J 33:293–306Google Scholar
  11. 11.
    Orem J, Mbidde EK, Lambert B et al (2007) Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7(3):166–175PubMedGoogle Scholar
  12. 12.
    Hesseling P, Molyneux E, Kamiza S et al (2009) Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. Ann Trop Paediatr 29(1):29–34PubMedCrossRefGoogle Scholar
  13. 13.
    Magrath IT (1991) African Burkitt’s lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13(2):222–246PubMedCrossRefGoogle Scholar
  14. 14.
    Mbulaiteye SM, Biggar RJ, Bhatia K et al (2009) Sporadic childhood Burkitt lymphoma incidence in the United States during 1992–2005. Pediatr Blood Cancer 53(3):366–370PubMedCrossRefGoogle Scholar
  15. 15.
    Mwando OW, Rochford R, Moorman AM et al (2004) Burkitt lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 8:68–77Google Scholar
  16. 16.
    Owuru L, Yebonh FA, Osei-Akolo A (2010) Clinical and epidemiological characteristics of Burkitt’s lymphoma: an eight year case study at Komfor Anokye teaching hospital Ghana. Br J Biomed Sci 87:9–14Google Scholar
  17. 17.
    Newton R, Ziegler J, Beral V et al (2001) A case–control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer 92(5):622–627PubMedCrossRefGoogle Scholar
  18. 18.
    Sinfield RL, Molyneux EM, Banda K et al (2007) Spectrum and presentation of pediatric malignancies in the HIV era: experience from Blantyre, Malawi, 1998–2003. Pediatr Blood Cancer 48(5):515–520PubMedCrossRefGoogle Scholar
  19. 19.
    Orem J, Maganda A, Mbidde EK et al (2009) Clinical characteristics and outcome of children with Burkitt lymphoma in Uganda according to HIV infection. Pediatr Blood Cancer 52(4):455–458PubMedCrossRefGoogle Scholar
  20. 20.
    Chintu C, Athale UH, Patil PS (1995) Childhood cancers in Zambia before and after the HIV epidemic. Arch Dis Child 73(2):100–104PubMedCrossRefGoogle Scholar
  21. 21.
    Mutalima N, Molyneux E, Jaffe H et al (2008) Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case–control study. PLoS One 3(6):e2505PubMedCrossRefGoogle Scholar
  22. 22.
    MacNeil A, Sumba OP, Lutzke ML et al (2003) Activation of the Epstein-Barr virus lytic cycle by the latex of the plant Euphorbia tirucalli. Br J Cancer 88(10):1566–1569PubMedCrossRefGoogle Scholar
  23. 23.
    van den Bosch CA (2004) Is endemic Burkitt’s lymphoma an alliance between three infections and a tumour promoter? Lancet Oncol 5(12):738–746PubMedCrossRefGoogle Scholar
  24. 24.
    Tabuti JR, Dhillion SS, Lye KA (2003) Ethnoveterinary medicines for cattle (Bos indicus) in Bulamogi county, Uganda: plant species and mode of use. J Ethnopharmacol 88(2–3):279–286PubMedCrossRefGoogle Scholar
  25. 25.
    Shiramizu B, Barriga F, Neequaye J et al (1991) Patterns of chromosomal breakpoint locations in Burkitt’s lymphoma: relevance to geography and Epstein-Barr virus association. Blood 77(7):1516–1526PubMedGoogle Scholar
  26. 26.
    Pelicci PG, Knowles DM, Magrath I et al (1986) Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 83(9):2984–2988PubMedCrossRefGoogle Scholar
  27. 27.
    Bellan C, Lazzi S, Hummel M et al (2005) Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 106(3):1031–1036PubMedCrossRefGoogle Scholar
  28. 28.
    Mwando OW (2004) Aspects of epidemiological and clinical features of patients with central nervours system Burkitt’s lymphoma in Kenya. East Afr Med J 8(suppl):897–903Google Scholar
  29. 29.
    Israels T, van de Wetering MD, Hesseling P (2009) Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi. Pediatr Blood Cancer 53(1):47–52PubMedCrossRefGoogle Scholar
  30. 30.
    Unicef (2011) The State of the World’s Children 2011Google Scholar
  31. 31.
    Nelson M, Perkins SL, Dave BJ et al (2010) An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG-5961. Br J Haematol 148(4):600–610PubMedCrossRefGoogle Scholar
  32. 32.
    Jaffe ES, Harris NL, Stein H et al (2001) WHO classification. Tumours of haematopoietic and lymphoid tissues. LyonGoogle Scholar
  33. 33.
    van Noorden S, Lampert IA, Xue SA et al (2011) Burkitt’s lymphoma: maximising the use of fine needle aspirates by long-term preservation for diagnosis and research. Trans R Soc Trop Med Hyg 105(2):86–94PubMedCrossRefGoogle Scholar
  34. 34.
    Hesseling P, Broadhead R, Mansvelt E et al (2005) The 2000 Burkitt lymphoma trial in Malawi. Pediatr Blood Cancer 44(3):245–250PubMedCrossRefGoogle Scholar
  35. 35.
    Hesseling PB, Molyneux E, Tchintseme F et al (2008) Treating Burkitt’s lymphoma in Malawi, Cameroon, and Ghana. Lancet Oncol 9(6):512–513PubMedCrossRefGoogle Scholar
  36. 36.
    Patte C, Auperin A, Michon J et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11):3370–3379PubMedCrossRefGoogle Scholar
  37. 37.
    Oettgen HF, Burkitt D, Burchenal JH (1963) Malignant lymphoma involving the jaw in African children: treatment with Methotrexate. Cancer 16:616–623PubMedCrossRefGoogle Scholar
  38. 38.
    Burkitt D, Hutt MS, Wright DH (1965) African lymphoma: preliminary observations on response to therapy. Cancer 18:399–410PubMedCrossRefGoogle Scholar
  39. 39.
    Clifford P (1968) Treatment of Burkitt’s lymphoma. Lancet 1(7542):599PubMedCrossRefGoogle Scholar
  40. 40.
    Morrow RH, Pike MC, Kisuule A (1967) Survival of Burkitt’s lymphoma patients in Mulago Hospital, Uganda. Br Med J 4(5575):323–327PubMedCrossRefGoogle Scholar
  41. 41.
    Ziegler JL, Morrow RH, Fass L et al (1970) Treatment of Burkitt’s tumor with cyclophosphamide. Cancer 26(2):474–484PubMedCrossRefGoogle Scholar
  42. 42.
    Nkrumah FK, Perkins IV, Biggar RJ (1977) Combination chemotherapy in abdominal Burkitt’s lymphoma. Cancer 40(4):1410–1416PubMedCrossRefGoogle Scholar
  43. 43.
    Magrath I (1990) Small non-cleaved lymphoma. In: The non-Hodgkin’s lymphoma. Edward Arnold, London, p 256Google Scholar
  44. 44.
    Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas, dissimilarities from lymphomas in adults. Semin Oncol 7:332–339PubMedGoogle Scholar
  45. 45.
    Patte C, Auperin A, Gerrard M et al (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109(7):2773–2780PubMedGoogle Scholar
  46. 46.
    Patte C, Michon J, Frappaz D et al (1994) Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 7(2):339–348PubMedCrossRefGoogle Scholar
  47. 47.
    Burkitt D (1967) Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 20(5):756–759PubMedCrossRefGoogle Scholar
  48. 48.
    Ziegler JL, DeVita VT, Graw RG Jr et al (1976) Combined modality treatment of American Burkitt’s lymphoma. Cancer 38(6):2225–2231PubMedCrossRefGoogle Scholar
  49. 49.
    Link MP, Shuster JJ, Donaldson SS et al (1997) Treatment of children and young adults with early-stage non-Hodgkin’s lymphoma. N Engl J Med 337(18):1259–1266PubMedCrossRefGoogle Scholar
  50. 50.
    Ziegler JL, Bluming AZ (1971) Intrathecal chemotherapy in Burkitt’s lymphoma. Br Med J 3(5773):508–512PubMedCrossRefGoogle Scholar
  51. 51.
    Traore F, Coze C, Atteby JJ et al (2011) Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 56(1):70–76PubMedCrossRefGoogle Scholar
  52. 52.
    Hesseling PB, Njume E, Kouya F, Katayi T, Wharin P, Tamannai M, et al. The Cameroon 2008 Burkitt lymphoma protocol: improved event-free survival with treatment adapted to disease stage and the response to induction therapy. Pediatr Hematol Oncol 2012 Mar;29(2):119–129PubMedCrossRefGoogle Scholar
  53. 53.
    Hesseling PB (2000) The SIOP burkitt lymphoma pilot study in Malawi, Africa. Med Pediatr Oncol 34(2):142PubMedCrossRefGoogle Scholar
  54. 54.
    Harif M, Barsaoui S, Benchekroun S et al (2008) Treatment of B-cell lymphoma with LMB modified protocols in Africa – report of the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer 50(6):1138–1142PubMedCrossRefGoogle Scholar
  55. 55.
    El Kababri M, Mrimi F, Loumatine K (2009) Treatment of childhood Burkitt lymphoma in North Africa: a study of the French-African Pediatric Oncology Group (G.F.A.O.P.). Hematology Meeting Reports 3:5:88Google Scholar
  56. 56.
    Ahmad N, Zaidi A, Badar F et al (2010) Clinical characteristics and outcome analysis of pediatric B-cell non-Hodgkin’s lymphoma. Experience with FAB-LMB 96 and UKCCSG B-cell NHL guidelines in a developing country. Asia Pac J Clin Oncol 6(1):49–56PubMedCrossRefGoogle Scholar
  57. 57.
    Wessels G, Hesseling PB (2000) High-dose intense chemotherapy in South African children with B-cell lymphoma: morbidity, supportive measures and outcome. Med Pediatr Oncol 34:143–146CrossRefGoogle Scholar
  58. 58.
    Moleti ML, Al-Hadad SA, Al-Jadiry MF et al (2011) Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. Pediatr Blood Cancer 56:560–567PubMedCrossRefGoogle Scholar
  59. 59.
    Katona P, Katona-Apte J (2008) The interaction between nutrition and infection. Clin Infect Dis 46(10):1582–1588PubMedCrossRefGoogle Scholar
  60. 60.
    Sala A, Pencharz P, Barr RD (2004) Children, cancer, and nutrition – a dynamic triangle in review. Cancer 100(4):677–687PubMedCrossRefGoogle Scholar
  61. 61.
    Manary MJ (2006) Local production and provision of ready-to-use therapeutic food (RUTF) spread for the treatment of severe childhood malnutrition. Food Nutr Bull 27(3 Suppl):S83–S89PubMedGoogle Scholar
  62. 62.
    Collins JJ (2001) Cancer pain management in children. Eur J Pain 5(Suppl A):37–41PubMedCrossRefGoogle Scholar
  63. 63.
    Nkrumah FK, Perkins IV (1976) Burkitt’s lymphoma: a clinical study of 110 patients. Cancer 37(2):671–676PubMedCrossRefGoogle Scholar
  64. 64.
    Phillips JA, Griffin BE (2007) Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt’s lymphoma. Trans R Soc Trop Med Hyg 101(12):1265–1269PubMedCrossRefGoogle Scholar
  65. 65.
    Stimson L, Wood V, Khan O et al (2009) HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 20(8):1293–1302PubMedCrossRefGoogle Scholar
  66. 66.
    Pena A, Ortiz A, Gamboa A, Garrido C (2009) Preliminary results of a multicenter BFM-based study for B-cell malignancies in Central America. Hematology Meeting Reports 3:5:90PubMedCrossRefGoogle Scholar
  67. 67.
    Klumb CE, Apa AG, Carrico MK (2009) Long-term outcome of children with B-non-Hodgkin’s lymphoma: results from Brazilian National Cancer Institute. Hematology Meeting Reports 3:5:15PubMedCrossRefGoogle Scholar
  68. 68.
    Chantada G, Zubizarreta P, Felice MS et al (2009) Results of a modified BFM strategy for the treatment of B-cell malignancies in Argentina. 3:5: 26PubMedCrossRefGoogle Scholar
  69. 69.
    Woessmann W, Seidemann K, Mann G et al (2005) The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 105(3):948–958PubMedCrossRefGoogle Scholar

Copyright information

© Springer New York 2013

Authors and Affiliations

  • Elizabeth Molyneux
    • 1
  • Trijn Israels
    • 2
  • Thomas Walwyn
    • 3
  1. 1.Paediatric DepartmentCollege of Medicine, Queen Elizabeth Central HospitalBlantyreC.Africa
  2. 2.Department of Pediatric OncologyVU University Medical CenterAmsterdamThe Netherlands
  3. 3.Princess Margaret Hospital for ChildrenPerthWestern Australia

Personalised recommendations